Pharmacia & Upjohn's Xalatan will be available in late summer for second-line use in glaucoma.
Executive Summary
PHARMACIA & UPJOHN XALATAN OPHTHALMIC WILL BE AVAILABLE IN LATE SUMMER, the company said following June 5 FDA approval of Xalatan for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are either intolerant of or insufficiently responsive to another intraocular pressure-lowering product. The approval comes approximately one year after Pharmacia's submission of NDA 20-597 for latanoprost solution on June 14, 1995. Xalatan was designated a priority review by FDA.